Stapokibart  (Synonyms: CM310)

Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (K_D values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis)^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

Stapokibart binds to IL-4Rα from human, cynomolgus monkey, and rat with K_D values of 0.25 nM, 1.50 nM, and 2.75 nM, respectively^[2].
Stapokibart blocks the interaction of IL-4 with IL-4Rα with an IC₅₀ of 0.40 nM^[2].
Stapokibart inhibits IL-4-induced STAT6 activation with an IC₅₀ of 0.039 nM and IL-13-induced STAT6 activation with an IC₅₀ of 0.041 nM^[2].
Stapokibart inhibits IL-4-induced TF-1 cell proliferation with an IC₅₀ of 1.75 nM and IL-13-induced proliferation with an IC₅₀ of 0.13 nM^[2].
Stapokibart suppresses IL-4-induced CD23 upregulation on Ramos cells with an IC₅₀ of 0.53 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Stapokibart (25-100 mg/kg; s.c.) exerts protective effects by inhibiting airway inflammation and reducing inflammatory cytokine levels in IL-4/IL-13-induced airway inflammation rats^[2].
Stapokibart (25-100 mg/kg; s.c.) improves Ovalbumin-induced rhinitis and AD-like dermatitis in rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3566  [NCBI]

P24394

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.3 kDa

2734715-10-5

Liquid

Colorless to light yellow

[Stapokibart]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Yuan Zhang, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023 Jul 5:61:102076.  [Content Brief]

  [2]. Liu W, et al. Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation. iScience. 2024 Aug 13;27(9):110721.  [Content Brief]